Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2018 1
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for risperidone sandoz
Your search for risperidon-sandoz retrieved no results
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Lopez-Morinigo JD, Leucht S, Arango C. Lopez-Morinigo JD, et al. Pharmacopsychiatry. 2022 Sep;55(5):233-245. doi: 10.1055/a-1854-0185. Epub 2022 Jul 1. Pharmacopsychiatry. 2022. PMID: 35777418 Free PMC article. Review.
Evidence supported the efficacy of aripiprazole, clozapine, haloperidol, lurasidone, molindone, olanzapine, quetiapine, risperidone and paliperidone in EOS, all of which obtained approval for EOS either in Europe and/or in North-America. Cognition, functioning and quality …
Evidence supported the efficacy of aripiprazole, clozapine, haloperidol, lurasidone, molindone, olanzapine, quetiapine, risperidone a …
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Milosavljevic F, et al. JAMA Psychiatry. 2021 Mar 1;78(3):270-280. doi: 10.1001/jamapsychiatry.2020.3643. JAMA Psychiatry. 2021. PMID: 33237321 Free PMC article.
RESULTS: Based on the data derived from 94 unique studies and 8379 unique individuals, the most profound differences were observed in the patients treated with aripiprazole (CYP2D6 PM plus IM vs NM RoM, 1.48; 95% CI, 1.41-1.57; 12 studies; 1038 patients), haloperidol lactate (CYP …
RESULTS: Based on the data derived from 94 unique studies and 8379 unique individuals, the most profound differences were observed in the pa …
Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.
Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, Salanti G, Davis JM. Leucht S, et al. JAMA Psychiatry. 2021 Nov 1;78(11):1238-1248. doi: 10.1001/jamapsychiatry.2021.2130. JAMA Psychiatry. 2021. PMID: 34406325 Free PMC article.
In a subgroup analysis of patients in remission, a plateau was reached earlier, at approximately 2.5-mg/d risperidone equivalent. CONCLUSIONS AND RELEVANCE: The findings of this meta-analysis suggest that doses higher than approximately 5-mg/d risperidone equivalent …
In a subgroup analysis of patients in remission, a plateau was reached earlier, at approximately 2.5-mg/d risperidone equivalent. CON …
Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis.
Wu H, Siafis S, Wang D, Burschinski A, Schneider-Thoma J, Priller J, Davis JM, Leucht S. Wu H, et al. Eur Neuropsychopharmacol. 2023 Jul;72:40-49. doi: 10.1016/j.euroneuro.2023.03.015. Epub 2023 Apr 17. Eur Neuropsychopharmacol. 2023. PMID: 37075639
In patients with acute exacerbations of chronic schizophrenia, from moderate to high certainty of evidence, our analysis showed that sertindole and quetiapine carried negligible risks for akathisia across examined doses (flat curves), while most of the other antipsychotics had th …
In patients with acute exacerbations of chronic schizophrenia, from moderate to high certainty of evidence, our analysis showed that sertind …
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, Merenlender-Wagner A, Sharon N, Davis GL 3rd, Suett M, Franzenburg KR, Correll CU. Kane JM, et al. Lancet Psychiatry. 2023 Dec;10(12):934-943. doi: 10.1016/S2215-0366(23)00288-2. Epub 2023 Nov 2. Lancet Psychiatry. 2023. PMID: 37924833 Clinical Trial.
BACKGROUND: TV-46000 is a long-acting, subcutaneous, antipsychotic agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension that was approved in April, 2023 for subcutaneous use. The aim of the phase 3 Risperidone S …
BACKGROUND: TV-46000 is a long-acting, subcutaneous, antipsychotic agent that combines risperidone and an innovative, copolymer-based …
Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.
Procyshyn RM, Chau A, Fortin P, Jenkins W. Procyshyn RM, et al. Can J Psychiatry. 2004 Sep;49(9):601-6. doi: 10.1177/070674370404900905. Can J Psychiatry. 2004. PMID: 15503731 Review.
This study attempts to determine the prevalence and outcomes of industry-sponsored trials involving clozapine, risperidone, or olanzapine. METHODS: We searched the literature from January 1, 1990, to December 31, 2001, to capture all eligible clinical trials involving cloz …
This study attempts to determine the prevalence and outcomes of industry-sponsored trials involving clozapine, risperidone, or olanza …
The efficacy and safety of risperidone for the treatment of geriatric psychosis.
Hwang JP, Yang CH, Yu HC, Chang JW, Cheng CY, Tsai SJ. Hwang JP, et al. J Clin Psychopharmacol. 2001 Dec;21(6):583-7. doi: 10.1097/00004714-200112000-00007. J Clin Psychopharmacol. 2001. PMID: 11763005
Assessment for drug efficacy using the Brief Psychiatric Rating Scale, Sandoz Clinical Assessment-Geriatric scale, and Clinical Global Impression scale was conducted at baseline and also at 4 weeks subsequent to risperidone treatment commencement. Subsequent to comm …
Assessment for drug efficacy using the Brief Psychiatric Rating Scale, Sandoz Clinical Assessment-Geriatric scale, and Clinical Globa …
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Bergman H, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD000459. doi: 10.1002/14651858.CD000459.pub3. Cochrane Database Syst Rev. 2018. PMID: 29409162 Free PMC article. Review.
One trial is ongoing.There was low-quality evidence of a clear difference on no clinically important improvement in TD favouring switch to risperidone compared with antipsychotic cessation (with placebo) (1 RCT, 42 people, RR 0.45 CI 0.23 to 0.89, low-quality evidence). .. …
One trial is ongoing.There was low-quality evidence of a clear difference on no clinically important improvement in TD favouring switch to …
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis.
Huhn M, Arndt T, Schneider-Thoma J, Leucht S. Huhn M, et al. Ther Adv Psychopharmacol. 2022 Jun 24;12:20451253221097261. doi: 10.1177/20451253221097261. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 35774251 Free PMC article.
Antipsychotics had a higher risk for tachycardia events compared with placebo [N = 37, n = 7827, risk ratio (RR) = 1.83, 95% confidence interval (CI) = 1.40-2.41], with large differences between the individual substances (iloperidone RR = 14.05, chlorpromazine RR = 4.84, loxapine …
Antipsychotics had a higher risk for tachycardia events compared with placebo [N = 37, n = 7827, risk ratio (RR) = 1.83, 95% confidence inte …
Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data.
Greil W, de Bardeci M, Müller-Oerlinghausen B, Nievergelt N, Stassen H, Hasler G, Erfurth A, Cattapan K, Rüther E, Seifert J, Toto S, Bleich S, Schoretsanitis G. Greil W, et al. Int J Bipolar Disord. 2023 Oct 15;11(1):34. doi: 10.1186/s40345-023-00313-8. Int J Bipolar Disord. 2023. PMID: 37840048 Free PMC article.
We compared aripiprazole, carbamazepine, lithium, olanzapine, quetiapine, risperidone, and valproate to lamotrigine. Additional analyses related to different mood stabilizers as reference medication were performed. ...
We compared aripiprazole, carbamazepine, lithium, olanzapine, quetiapine, risperidone, and valproate to lamotrigine. Additional analy …
11 results